Deals channel feed – Endpoints News

Deals channel feed

Would AbbVie’s top execs really pull the trigger on a $30B M&A deal? Why, yes, actually

7 years ago

API manufacturer Cambrex buys Halo Pharma for $425M — venturing into finished dose manufacturing

7 years ago

Sangamo puts down $84M to acquire TxCell, diving into CAR-Treg space, autoimmune diseases

7 years ago

Nabbing late-stage drug, PTC acquires gene therapy startup Agilis for $200M in cash/stock

7 years ago

By the numbers: Series A rounds are busting out, platforms are in, M&A is down, valuations surge and 2018 looks wicked big

7 years ago

Otsuka jumps into the US biotech M&A game, bagging Visterra in $430M buyout

8 years ago

Under pressure from shareholders, BioCryst drops plan to merge with Idera

8 years ago

Takeda posts 'for-sale' sign on company's ancestral home in Osaka in effort to fund Shire buyout

8 years ago

Catalent inks $133M deal to buy Juniper Pharmaceuticals, adding UK development services

8 years ago

Amazon snaps up online pharmacy startup PillPack in latest move to disrupt healthcare

8 years ago

Anemia specialist Akebia merges with Keryx on the eve of a blockbuster brawl with FibroGen

8 years ago

Takeda’s old guard loses a key battle against $62B Shire buyout — but a much bigger threat looms

8 years ago

Roche bags full control of Foundation Medicine in $2.4B follow-up buyout

8 years ago

Buyout buzz bumps Madrigal stock further north, stoking the industry's NASH obsession

8 years ago

Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team — acquired 3 years ago

8 years ago

Bitterly opposed old guard at Takeda wages a last-ditch fight to block 'foreign blood's' $62B Shire buyout

8 years ago

With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?

8 years ago

Merck data and a tumbling stock price cost Armo's investors $320M-plus in Eli Lilly buyout

8 years ago

Takeda bags $280M, sells off its stake in a China drug JV ahead of $62B Shire buyout

8 years ago

Will Shire's top R&D talent bolt now that Takeda has struck a merger agreement?

8 years ago

Vectalys and FlashCell merge into Flash Therapeutics, loaded with RNA pipeline and manufacturing set-up

8 years ago

Eli Lilly's oncology R&D spree continues with $576M deal to buy a startup and reel back Aurora A drug

8 years ago

Whisky, secrets, and code names: behind-the-scenes of Takeda's $62B Shire bid - Bloomberg

8 years ago

Playing catch-up, Eli Lilly swoops in with $1.6B cash deal for Armo Bio and its promising PhIII cancer drug

8 years ago

First page Previous page 109 110 111112113 114 115 Next page Last page